TRAIL on trial: preclinical advances in cancer therapy

被引：232

作者：

Stuckey, Daniel W. ^{[1
,2
]}

Shah, Khalid ^{[1
,2
,3
,4
]}

机构：

[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02114 USA

[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA

[3] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA

[4] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA

来源：

TRENDS IN MOLECULAR MEDICINE | 2013年 / 19卷 / 11期

关键词：

TRAIL; apoptesis; cancer; targeted therapy; stem cells; APOPTOSIS-INDUCING LIGAND; MESENCHYMAL STEM-CELLS; MONOCLONAL-ANTIBODY; TUMORICIDAL ACTIVITY; DOWN-REGULATION; GLIOMA-CELLS; IN-VITRO; PHASE-I; DEATH; DELIVERY;

D O I：

10.1016/j.molmed.2013.08.007

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand, or TRAIL, is a promising anticancer agent as it can induce apoptosis in a wide range of cancers whilst generally sparing non-malignant cells. However, the translation of TRAIL into the clinic has been confounded by its short half-life, inadequate delivery methods, and TRAIL-resistant cancer cell populations. In this review, we discuss how TRAIL has been functionalized to diversify its traditional tumor-killing role and novel strategies to facilitate its effective deployment in preclinical cancer models. The successes and failures of the most recent clinical trials using TRAIL agonists are highlighted and we provide a perspective for improving its clinical implementation.

引用

页码：685 / 694

页数：10

共 80 条

[61]

Schneider P, 2000, METHOD ENZYMOL, V322, P325

[62] Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy [J].